Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well giving ofatumumab together with bortezomib works in
treating patients with previously untreated Waldenstrom macroglobulinemia. Monoclonal
antibodies, such as ofatumumab and bortezomib, can block cancer growth in different ways.
Some block the ability of cancer cells to grow and spread. Others find cancer cells and help
kill them or carry cancer-killing substances to them. Giving ofatumumab together with
bortezomib may be a better way to block cancer growth